For Healthcare Professionals

A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC


About the study

This is a Phase I/II study designed to evaluate if experimental anti-TIGIT/anti-PD-1 bispecific antibody rilvegostomig (AZD2936) is safe, tolerable and efficacious in participants with Advanced or Metastatic Non-small Cell Lung Cancer.

Who can take part

You may be eligible to participate in the study if you meet the following criteria:


Inclusion Criteria:

  1. Written informed consent
  2. Aged 18 or above
  3. Part A and Part B: Unresectable stage III or stage IV squamous or non-squamous NSCLC not amenable to curative surgery or radiation. Part C and Part D: Stage IV squamous or non-squamous NSCLC not amenable to curative surgery or radiation.
  4. Documented PD-L1 expression by PD-L1 IHC per local report.
  5. Part A and Part B: Confirmed progression during treatment with a CPI-including regimen.
  6. Part C and Part D: No prior I/O treatment for NSCLC.
  7. ECOG performance status of 0 or 1 at enrolment.
  8. Life expectancy of ≥ 12 weeks at enrolment.
  9. Have at least 1 measurable lesion per RECIST v1.1.
  10. Adequate bone marrow, liver and kidney function


Exclusion Criteria:

  1. Sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) fusion
  2. Documented test result for any other known genomic alteration for which a targeted therapy is approved in first line per local standard of care (e.g. ROS1, NTRK fusions, BRAF, V600E mutation)
  3. Previous treatment with an anti-TIGIT therapy
  4. Any concurrent chemotherapy, radiotherapy, investigational, biologic, or hormonal therapy for cancer treatment.
  5. Part A and Part B: Primary or secondary resistance after treatment with 2 or more regiments including a CPI.
  6. Part C and Part D: Any prior systemic treatment with an immune-oncology agent (Treatment with one previous systemic chemotherapy will be allowed).
  7. Primary or secondary resistance after treatment with 2 or more regimens including a CPI.
  8. Symptomatic central nervous system (CNS) metastasis.
  9. Thromboembolic event within 3 months prior to enrolment.
  10. Other invasive malignancy within 2 years prior to screening.
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.

Study’s details


Non-Small-Cell Lung Carcinoma

Age (in years)

18 - 130


Phase 1/Phase 2

Participants needed


Est. Completion Date

Jan 27, 2026

Treatment type



AstraZeneca identifier


Study number


Understanding Clinical Trials

Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?


Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.